All News about Arcutis Biotherapeutics Inc
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
July 10, 2024
Via Benzinga
Exposures
Product Safety
Via Benzinga
Via GlobeNewswire
Via Benzinga
Via Benzinga
Via GlobeNewswire
Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|